New cocktail shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT04109924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of three drugs—TAS-102, irinotecan, and bevacizumab—in 42 people with advanced colorectal cancer that had spread or couldn't be removed. The goal was to see if this mix could slow tumor growth better than standard treatments. Participants received the drugs intravenously and by mouth in cycles, and researchers measured how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAS-102, irinotecan, and bevacizumab
- What this could lead to
- If this works, it could provide a new treatment option for people with advanced colorectal cancer who have already tried standard therapies.
- What could go wrong
- This is a small, early-phase study (42 people) without a comparison group, so results may not apply broadly. The drug combination can cause side effects like low blood counts and diarrhea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a common muscle relaxant make radiation deadlier for rectal cancer?
- Experimental drug combo targets Hard-to-Treat GI cancers
- New combo aims to spare rectal cancer patients from surgery
- Wheat germ supplement studied for immune boost in advanced cancer